INTRODUCTION
Candida albicans is the predominant cause of virtually all types of candidiasis (Filler & Sheppard, 2006) . Coinciding with the occurrence of azole-resistant isolates, much effort has been undertaken to solve this by: (i) searching for new antifungal agents, such as posaconazole and ravuconazole, although new drugs for the treatment of these resistant infections are unlikely to appear soon enough and in sufficient numbers (Andes et al., 2006) ; (ii) developing new formulations of established agents, such as itraconazole (ITC), an intravenous formulation of which has overcome the poor and erratic bioavailability of the oral capsule formulation (Pfaller et al., 2005) ; and (iii) improving the efficacy of antifungal agents by using combination therapy, for example combining agents with different antifungal mechanisms (Barchiesi et al., 1998; Ghannoum et al., 1995; Girmenia et al., 2003) or combining antifungal and nonantifungal agents (Cruz et al., 2002; Quan et al., 2006) .
Recently, the anti-arrhythmic drug amiodarone (AMD) was reported to have potent fungicidal activity against a broad range of fungi (Cryptococcus, Saccharomyces, Aspergillus, Candida and Fusarium) by testing the doubling times or cell weight (Courchesne, 2002) . Researchers also showed that low doses of AMD acted synergistically with fluconazole (FLC) against C. albicans SC5314 by detecting the post-antifungal effect (Gupta et al., 2003) . These results made us interested in a more detailed study of the in vitro activity of AMD in combination with azoles [FLC, ITC and voriconazole (VRC) ] by conventional methods. In this paper, we present the combined effects of the three azoles and AMD against resistant C. albicans by multiple methods of testing and assessing. The strains used were new clinical isolates rather than standard C. albicans (Gupta et al., 2003) . 21 for ITC and VRC, and 0.125 to 8 mg ml 21 for AMD. Each isolate was tested three times on different days. In order to assess the nature and intensity of the in vitro interactions between the three azoles and AMD, the data obtained were analysed using models based on two non-interaction theories: the Loewe additivity (LA) and the Bliss independence (BI) theories.
The non-parametric approach of LA is based on the fractional inhibitory concentration (FIC) index (FICI) model expressed as: SFIC5FIC A +FIC B 5(MIC of drug A in combination/MIC of drug A alone)+(MIC of drug B in combination/MIC of drug B alone) (Te Dorsthorst et al., 2004) . Among all of the SFIC values calculated for each dataset, the FICI was determined as SFIC min (the lowest SFIC) when SFIC max (the highest SFIC) was less than 4; otherwise, the FICI was determined as SFIC max (Meletiadis et al., 2003) . Synergy and antagonism were defined by FICIs of ¡0.5 and .4, respectively. An FICI result of .0.5 but ¡4 was considered indifferent (Odds, 2003) .
The non-parametric approach of BI is based on the Prichard model defined as E i 5E A 6E B , where E i is the predicted percentage of growth of the theoretical combination of drugs A and B, respectively, and E A and E B are the experimental percentages of growth of each drug acting alone, respectively. Interaction is described by the difference (DE) between the predicted and measured percentages of growth at various concentrations. Because of the nature of the interaction testing with microtitre plates and a twofold dilution of either drug, this results in a DE for each drug combination. When the mean DE was positive and its 95 % confidence interval (CI) among the replicates did not include 0, statistically significant (SS) synergy was claimed; when the DE was negative and its 95 % CI did not include 0, SS antagonism was claimed. In any other case, BI was concluded. The DE values obtained for each combination can be depicted on the z-axis to construct a 3D surface plot. Peaks above and below the 0 plane indicate synergistic and antagonistic combinations, respectively, whilst the 0 plane indicates the absence of SS interaction. As the plot only shows the interactions for each separate combination of the concentrations, a value is needed to summarize the interaction surface. This was achieved by calculating the sum percentage of all SS synergistic (SSYN) and antagonistic (SANT) interactions. Interactions with ,100 % of SS interactions were considered weak, those with 100-200 % of SS interactions were considered moderate, and those with .200 % of SS interactions were considered strong. In addition, the numbers of SS synergistic and antagonistic combinations among the 77 combinations tested were calculated for each strain (Afeltra et al., 2004) .
Time-kill assay. We investigated the activity of AMD with or without azoles against one resistant strain (CA10) at a starting inoculum of 10 5 c.f.u. ml
21
. A set of solutions was prepared: a growth control (drug-free), AMD alone (4 mg ml 21 ), azoles alone (8 mg ml 21 for FLC, 0.5 mg ml 21 for ITC and VRC) and combinations of AMD with each azole. All solutions were incubated at 35 uC without agitation (Klepser et al., 1998) . At predetermined time points (0, 6, 12, 24 and 48 h), a 100 ml sample was removed from each solution and serially diluted. A 100 ml aliquot from each dilution was then streaked onto a Sabouraud dextrose agar plate to perform colony counting after incubation for 48 h. A colorimetric reduction assay was carried out using 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT; Sigma). XTT was dissolved at 0.5 g l 21 in Ringer's lactate, sterilized through a 0.22 mm filter, stored at 270 uC and maintained at 4 uC when in use. Before use, 100 mM menadione in acetone was added to a final concentration of 10 mM (Ramage et al., 2001) . At the same predetermined time points, another 100 ml sample was removed from each solution into a 96-well flat-bottomed microtitre plate and a 100 ml aliquot of XTT/menadione solution was added to each well. The plate was incubated in the dark for up to 2 h at 35 uC. After this, the absorbance of the XTT reduction product, formazan, was read at 492 nm for each well using a plate reader (Lewis & Kontoyiannis, 2005) . All experiments were conducted in triplicate.
A standard correlation between viable cell counts from colony counting and optical density values from the XTT reduction assay was used to transform XTT reduction results into cell counts and to compare them. The following criteria were used for both methods to interpret time-kill results: synergy, a ¢2 log 10 decrease in c.f.u. ml 21 compared with the most active constituent; antagonism, a ¢2 log 10 increase in c.f.u. ml 21 compared with the least active agent; additivity, a ,2 but .1 log 10 decrease in c.f.u. ml 21 compared with the most active agent; and indifference, a ,2 but .1 log 10 increase in c.f.u. ml 21 compared with the least active agent (Mukherjee et al., 2005) .
RESULTS AND DISCUSSION

Susceptibility and interaction of drugs
The MICs of FLC, ITC and VRC in each test, based on an 80 % reduction in growth, for C. parapsilosis ATCC 22019 were 4, 0.125 and 0.063 mg ml 21 , respectively, which are within the reference ranges. Table 1 summarizes the in vitro susceptibility of the drugs alone and in combination against C. albicans. The susceptibility of experimental isolates agreed well among the three azoles, indicating the existence of cross-resistance. Generally, for cross-resistant strains, the FICI ranged from 0.001 to 0.018 (much smaller than 0.5) and the percentages of synergistic interactions ranged from 691 to 2256 % (far beyond 100 %), suggesting a very strong enhanced antifungal effect of azoles by AMD, whilst there was predominantly no synergistic effect observed for the tested susceptible C. albicans isolates. To obtain a visual characteristic of the drug combinations, a 3D surface plot of FLC combined with AMD against strain CA10 was prepared (Fig. 1) .
In vitro interaction of two or more agents is dependent on the methodology used to generate the data, as well as on the way the results are analysed, resulting in variable as well as controversial conclusions (Meletiadis et al., 2003) . Compared with the FICI, the Prichard model not only allows an objective statistical criterion, but also fits all the experimental concentrations to construct a 3D graph to visualize the nature and intensity of drug combinations without arbitrarily choosing an end point (Te Dorsthorst et al., 2002) . Compared with the fully parametric and semi-parametric response surface approaches (Afeltra et al., 2004) , the Prichard model is not dependent on the data analysis program and the sigmoid dose-response, and thus does not fail to fit the data. Last but most importantly, the Prichard model had an excellent reproducibility for the 77 combinations calculated for each strain. Current methods based on the LA and BI models are associated with implicit assumptions about the interacting system (Tam et al., 2004) . Considering all of the above, we strongly advise the use of the Prichard model to assess the interaction between two drugs for its peerless advantages.
Time-kill curves of drug combinations
The optical density values from the XTT reduction assay were transformed into colony counts using the standard Fig. 2 . The results of AMD combined with the azoles from the time-kill study are shown in Table 2 . Synergistic interactions from chequerboard testing were confirmed by time-kill curves, although we had to convert the colony counting data from FLC with AMD and ITC with AMD into integers. Representative plots of log 10 c.f.u. ml 21 against time for the XTT reduction assay are shown in Fig. 3 . AMD alone had a very weak antifungal effect at 4 mg ml 21 at 48 h, but the fungistatic activity of azoles against the resistant strain (CA10) was dramatically enhanced by the addition of AMD. Given the initial inoculum of 10 5 c.f.u. ml
21
, the combination yielded, respectively, a mean decrease of 2.02, 2.04 and 2.08 log 10 c.f.u. ml 21 for FLC, ITC and VRC after incubation for 48 h. There were no obvious differences in features of drug action among the three combinations.
Time-kill curves provided growth kinetic information over time and gave a more detailed picture of the effect of drug combinations on cell viability (Mukherjee et al., 2005) . XTT is reduced by mitochondrial dehydrogenases of viable fungi into a water-soluble formazan product, which is measured by the absorbance at 492 nm (Kuhn et al., 2002) . Previous work showed an actual relationship between Candida cell number and XTT formazan signal (Kuhn et al., 2003) , so we carried out time-kill experiments using the XTT reduction assay and compared it with colony counting. Without the influence of filament formation, time-kill curves obtained using the XTT assay were as reliable as colony counting. The XTT assay remains a valuable tool for examining the growth and metabolism of yeast, whether in planktonic or biofilm form (Kuhn et al., 2003) , and may become a substitute for colony counting for its time-saving advantage.
Potential mechanisms of AMD that augment the antifungal effects of azoles
The action of azoles not only involves impeding ergosterol biosynthesis through the competitive inhibition of 14a-demethylase, which is a product of the ERG11 gene, but also leads to accumulation of 14-methylated sterol, which can cause disruption of fungal membranes (Morschhäuser, 2002; Ribeiro & Paula, 2007) . Our investigation illustrated that AMD used in combination with azoles acted synergistically against resistant C. albicans strains, whilst there was almost no synergistic activity seen against susceptible strains. Considering the effect of AMD in inhibiting L-type Ca 2+ channels and Na + /K + channels when treating atrial fibrillation in patients with left ventricular dysfunction and heart failure, we propose that the most likely mechanism of the synergistic effect would be a consequence of disrupted Ca 2+ homeostasis as reported by Gupta et al. (2003) . Other possible mechanisms whereby AMD could reduce the overexpression of genes encoding efflux pumps or azole target enzymes are still under study.
Although AMD can cause serious adverse effects, including anaemia (Nicolay et al., 2007) , corneal microdeposits, optic neuropathy/neuritis, blue-grey skin discoloration, photosensitivity, hypothyroidism, hyperthyroidism, pulmonary toxicity, peripheral neuropathy and hepatotoxicity (Vassallo & Trohman, 2007) , as one of the first-line agents of atrial fibrillation treatment, it is widely used in clinical situations. In addition, this study provides a new clue to antifungal mechanisms by considering the known actions of AMD, and suggests a way of treating resistant C. albicans infection through a drug combination approach.
In conclusion, our results highlight the promising role of AMD used in combination with azoles to treat serious resistant C. albicans infection. Prospective studies in appropriate animal models are required to develop therapeutic strategies for these combinations, and further studies in other types of fungi and with a larger number of strains are needed. Fig. 3 . Time-kill curves for strain CA10 obtained by XTT assay using 8 mg ml "1 for FLC (a) and 0.5 mg ml "1 for ITC (b) and VRC (c) combined with AMD at 4 mg ml "1
. &, Growth control; h, AMD alone; m, azole alone; g, azole combined with AMD.
